Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Hepatology
Metabolic Dysfunction-Associated Liver Diseases
Questions discussed in this category
How does presence of clinically significant portal hypertension change patient prognosis in MASLD?
1 Answer available
If you do not have easy access to Fibroscan, what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk stratify them?
1 Answer available
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
1 Answer available
23703
24248
22838
Papers discussed in this category
International journal of molecular sciences, 2022 Mar 13
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
Related Topics in Hepatology
General Hepatology
Gastroenterology
Metabolic Dysfunction-Associated Liver Diseases
Viral Hepatitis
Autoimmune Liver Disease
Alcohol-associated Liver Disease
Genetic Liver Disease
Portal Hypertension
Liver Tumors
Transplant Hepatology